Subsequent Events	3 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events FDA approval of TUDRIQEV On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. This approval is a significant milestone for the Company, and the commercial launch of TUDRIQEV is in progress. Equity offering On August 10, 2026, the Company completed an offering of (a) 9,701,490 shares of the Company’s common stock at an offering price of $12.06 per share and, (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at an offering price of $12.0599 per pre-funded warrant. The company received aggregate net proceeds of approximately $141.0 million after deducting fees and expenses of approximately $9.0 million.

Subsequent Events

3 Months Ended

Jun. 30, 2026

FDA approval of TUDRIQEV

On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. This approval is a significant milestone for the Company, and the commercial launch of TUDRIQEV is in progress.

Equity offering

On August 10, 2026, the Company completed an offering of (a) 9,701,490 shares of the Company’s common stock at an offering price of $12.06 per share and, (b) in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at an offering price of $12.0599 per pre-funded warrant. The company received aggregate net proceeds of approximately $141.0 million after deducting fees and expenses of approximately $9.0 million.